期刊文献+

肝癌患者树突状细胞融合肝癌细胞体外诱导特异性抗肝癌免疫 被引量:2

Eliciting specific antitumor immunity against hepatocellular carcinoma in vitro by fusions of HCC patient-derived dendritic cells with HCC cells
暂未订购
导出
摘要 目的:探讨肝癌(HCC)患者树突状细胞(DC)融合HCC细胞体外诱导同源T淋巴细胞产生特异性抗HCC免疫的效能. 方法:应用人重组粒细胞/巨噬细胞集落刺激因子(rhGM- CSF)和白介素-4(rhIL-4)对肝癌患者外周血单个核细胞进行体外诱导产生树突状细胞,流式细胞仪检测DC表面标志物表达水平,聚乙二醇融合DC与肝癌细胞HepG2,MTT法测定融合细胞(HepG2/DC)刺激同源T 淋巴细胞增生、分化能力,细胞毒性试验检测HepG2/ DC诱导的细胞毒T淋巴细胞(CTL)对HepG2的特异性杀伤作用. 结果:体外培养1 wk后的DC高度表达CDla,HLA- DR,CD54,CD80和CD86,融合细胞HepG2/DC刺激同源T淋巴细胞增值能力显著高于HepG2,HepG2+DC, DC及PBS,A值分别为0.816±0.019,0.541±0.020, 0.632±0.018,0.564±0.018,0.345±0.01 3(P<0.05), HepG2/DC活化的CTL对HepG2具有明显的特异性杀伤作用. 结论:HCC患者外周血DC融合HCC细胞可有效诱导同源T淋巴细胞产生特异性抗HCC免疫,可望成为一条HCC免疫治疗的有效途径. AIM: To investigate the ability of fusions of HCC patient-derived dendritic cells (DC) with HCC cells to induce au-tologous T lymphocytes to elicit specific immunity against HCC in vitro. METHODS: Dendritic cells isolated from HCC patient peripheral blood were cultured and proliferated in vitro for one week by using recombinant human granulocyte/mac-rophage-colony stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4). Expression of DC surface markers was assessed by flow cytometry. Fusions of DC with HepG2 cells (HepG2/DC) were achieved by polythyleneglycol (PEG). The ability of HepG2/DC to stimulate proliferation and differentiation of autologous T lymphocytes was assessed by MTT method, and the specific killing efficacy of HepG2/DC-induced cytotoxic T lymphocytes (CTL) to HepG2 was evaluated. RESULTS: Following one week culture, DC presented a high-level expression of CD1a, HLA-DR, CD54, CD80 and CD86. Fusions had remarkably greater ability to stimulate proliferation of autologous T lymphocytes in comparison with HepG2, HepG2+DC, DC and PBS, with an A value of 0.816± 0.019 vs 0.541±0.020,0.632±0.018,0.564±0.018,0.345±0.013, respectively (P<0.05). The HepG2/DC-activated CTLs showed a potent specific killing efficacy to HepG2. CONCLUSION: Fusions of HCC patient-derived DC with HCC cells can effectively stimulate autologous T lymphocytes to elicit specific antitumor immunity against HCC, and may represent as a promising approach of immunotherapy for HCC.
出处 《世界华人消化杂志》 CAS 2004年第4期774-777,共4页 World Chinese Journal of Digestology
基金 国家自然科学基金资助课题 No.30100180~~
  • 相关文献

参考文献11

二级参考文献46

  • 1Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量:214
  • 2[1]Engleman EG.Dendritic cells:potential role in cancer therapy.Cytotechnology,1997;25:1-8
  • 3[2]Li MS,Yuan AL,Zhang WD,Liu SD,Peng QR,Zhang YL.Dendritic cells from hepatocellur carcinoma patients induce efficient and specific anti-tumor immune response.Sh ijie Huaren Xiaohua Zazhi,1999;7:161-163
  • 4[3]Li MS,Yuan AL,Tan XH,Zhuang YA.Immune response induced by dendritic cells pulsed with tumor extracts in vivo inhibit growth of implanted tumor in nudes by inducing apoptosis of tumor cells.Zhongguo Zhongliu Linchuang,1999;6:222-224
  • 5[4]Ansari B,Coates PJ,Greenstein BD.In situ end-labeling detect DNA strand breaks in apoptosis and other physiological and pathological states.J Pathol,1993;170:1-4
  • 6[5]Banchereau J,Steinman RM.Dendritic cells and the control of immunity.Nature,1998;392:245-252
  • 7[4]Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F, Dupas B, Martin T, Nouel JF, Schnee M, Montigny P, D'Alincourt A, Hamy A, Paineau J, Le Neel JC, Le Borgne J, Galmiche JP.Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective casecontrol study with cost analysis. Aliment Pharmacol Ther 2002;16:1529-1538
  • 8[5]Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N,Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918-928
  • 9[6]Groupe d'Etude et de Traitement du Carcimome Hepatocelltaire.A comparison of lipiodol, chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261
  • 10[7]Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003; 237:171-179

共引文献492

同被引文献15

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部